Does the media refer more to BHC or CRNX?

In the previous week, Bausch Health Cos had 19 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 23 mentions for Bausch Health Cos and 4 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.14 beat Bausch Health Cos' score of 1.04 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BHC or LQDA?

Bausch Health Cos has higher revenue and earnings than Liquidia. Bausch Health Cos is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Cos $10.27B 0.23 $157M -$2.96 N/A Liquidia $158.32M 38.80 -$68.92M $1.37 50.09

Is BHC or LQDA more profitable?

Liquidia has a net margin of 30.74% compared to Bausch Health Cos' net margin of -10.12%. Liquidia's return on equity of 149.65% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -10.12% -561.95% 6.31% Liquidia 30.74% 149.65% 36.30%

Does the media favor BHC or LQDA?

In the previous week, Bausch Health Cos had 7 more articles in the media than Liquidia. MarketBeat recorded 23 mentions for Bausch Health Cos and 16 mentions for Liquidia. Bausch Health Cos' average media sentiment score of 1.04 beat Liquidia's score of 0.53 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LNTH or BHC more profitable?

Lantheus has a net margin of 17.69% compared to Bausch Health Cos' net margin of -10.12%. Lantheus' return on equity of 28.10% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Bausch Health Cos -10.12% -561.95% 6.31%

Does the media prefer LNTH or BHC?

In the previous week, Bausch Health Cos had 12 more articles in the media than Lantheus. MarketBeat recorded 23 mentions for Bausch Health Cos and 11 mentions for Lantheus. Lantheus' average media sentiment score of 1.26 beat Bausch Health Cos' score of 1.04 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BHC or BLTE?

In the previous week, Bausch Health Cos had 20 more articles in the media than Belite Bio. MarketBeat recorded 23 mentions for Bausch Health Cos and 3 mentions for Belite Bio. Bausch Health Cos' average media sentiment score of 1.04 beat Belite Bio's score of -0.75 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Bausch Health Cos (BHC) Competitors

$6.42 -0.39 (-5.73%)

As of 08/21/2026 03:58 PM Eastern

Compare

BHC vs. CRNX, LQDA, LNTH, BLTE, and AMRX

Should you buy Bausch Health Cos stock or one of its competitors? Bausch Health Cos's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bausch Health Cos compare to Crinetics Pharmaceuticals?

Bausch Health Cos (NYSE:BHC) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 24.61%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 4.36%. Given Bausch Health Cos' higher probable upside, analysts plainly believe Bausch Health Cos is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Bausch Health Cos has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bausch Health Cos has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.23	$157M	-$2.96	N/A
Crinetics Pharmaceuticals	$7.70M	1,166.63	-$465.32M	-$5.04	N/A

Bausch Health Cos has a net margin of -10.12% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Crinetics Pharmaceuticals' return on equity of -44.22% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Bausch Health Cos had 19 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 23 mentions for Bausch Health Cos and 4 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.14 beat Bausch Health Cos' score of 1.04 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bausch Health Cos beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Liquidia?

Bausch Health Cos (NYSE:BHC) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 24.61%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 42.94%. Given Liquidia's stronger consensus rating and higher probable upside, analysts plainly believe Liquidia is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Liquidia has a net margin of 30.74% compared to Bausch Health Cos' net margin of -10.12%. Liquidia's return on equity of 149.65% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Liquidia	30.74%	149.65%	36.30%

In the previous week, Bausch Health Cos had 7 more articles in the media than Liquidia. MarketBeat recorded 23 mentions for Bausch Health Cos and 16 mentions for Liquidia. Bausch Health Cos' average media sentiment score of 1.04 beat Liquidia's score of 0.53 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos has higher revenue and earnings than Liquidia. Bausch Health Cos is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.23	$157M	-$2.96	N/A
Liquidia	$158.32M	38.80	-$68.92M	$1.37	50.09

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bausch Health Cos has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Summary

Liquidia beats Bausch Health Cos on 12 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Bausch Health Cos (NYSE:BHC) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lantheus presently has a consensus target price of $108.11, indicating a potential upside of 8.14%. Bausch Health Cos has a consensus target price of $8.00, indicating a potential upside of 24.61%. Given Bausch Health Cos' higher possible upside, analysts clearly believe Bausch Health Cos is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Lantheus has higher earnings, but lower revenue than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.56B	4.19	$233.56M	$4.14	24.15
Bausch Health Cos	$10.27B	0.23	$157M	-$2.96	N/A

Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

In the previous week, Bausch Health Cos had 12 more articles in the media than Lantheus. MarketBeat recorded 23 mentions for Bausch Health Cos and 11 mentions for Lantheus. Lantheus' average media sentiment score of 1.26 beat Bausch Health Cos' score of 1.04 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to Bausch Health Cos' net margin of -10.12%. Lantheus' return on equity of 28.10% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Summary

Lantheus beats Bausch Health Cos on 11 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Belite Bio?

Bausch Health Cos (NYSE:BHC) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 24.61%. Belite Bio has a consensus price target of $205.80, indicating a potential upside of 27.78%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts plainly believe Belite Bio is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Bausch Health Cos has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, indicating that its stock price is 222% less volatile than the broader market.

In the previous week, Bausch Health Cos had 20 more articles in the media than Belite Bio. MarketBeat recorded 23 mentions for Bausch Health Cos and 3 mentions for Belite Bio. Bausch Health Cos' average media sentiment score of 1.04 beat Belite Bio's score of -0.75 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Belite Bio has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Belite Bio's return on equity of -11.84% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Belite Bio	N/A	-11.84%	-11.62%

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bausch Health Cos has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.23	$157M	-$2.96	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Summary

Bausch Health Cos beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Bausch Health Cos compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Bausch Health Cos (NYSE:BHC) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Amneal Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential downside of 1.36%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 24.61%. Given Bausch Health Cos' higher probable upside, analysts clearly believe Bausch Health Cos is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Bausch Health Cos had 23 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 23 mentions for Bausch Health Cos and 0 mentions for Amneal Pharmaceuticals. Bausch Health Cos' average media sentiment score of 1.04 beat Amneal Pharmaceuticals' score of 0.00 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
Bausch Health Cos	Positive

Amneal Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than Amneal Pharmaceuticals. Bausch Health Cos is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.12B	1.83	$72.06M	$0.49	36.55
Bausch Health Cos	$10.27B	0.23	$157M	-$2.96	N/A

Amneal Pharmaceuticals has a net margin of 5.05% compared to Bausch Health Cos' net margin of -10.12%. Bausch Health Cos' return on equity of -561.95% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Summary

Amneal Pharmaceuticals beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Cos	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.41B	$12.57B	$7.37B	$24.30B
Dividend Yield	N/A	2.61%	2.53%	3.70%
P/E Ratio	-2.17	789.80	272.60	30.31
Price / Sales	0.23	764.50	618.96	19.89
Price / Cash	0.88	96.77	78.62	32.49
Price / Book	-3.00	11.89	13.05	6.77
Net Income	$157M	$2.81B	$3.47B	$1.07B
7 Day Performance	-1.31%	1.77%	2.09%	-0.65%
1 Month Performance	44.11%	3.85%	6.64%	3.38%
1 Year Performance	-14.18%	6.56%	25.02%	14.90%

Bausch Health Cos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Cos	3.1862 of 5 stars	$6.42 -5.7%	$8.00 +24.6%	-14.2%	$2.41B	$10.27B	N/A	20,300	Trending News Analyst Upgrade Insider Trade Analyst Revision
CRNX Crinetics Pharmaceuticals	1.936 of 5 stars	$84.75 +0.1%	$81.00 -4.4%	+173.9%	$8.98B	$42.16M	N/A	210	Positive News
LQDA Liquidia	4.2921 of 5 stars	$77.70 +4.4%	$98.08 +26.2%	+155.7%	$6.66B	$450.91M	56.72	50	Insider Trade
LNTH Lantheus	3.5534 of 5 stars	$100.91 0.0%	$108.11 +7.1%	+71.7%	$6.59B	$1.54B	24.37	1,193	Positive News
BLTE Belite Bio	3.351 of 5 stars	$163.21 +0.3%	$205.80 +26.1%	+150.1%	$6.53B	N/A	N/A	10	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHC) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Cos (BHC) Competitors

BHC vs. CRNX, LQDA, LNTH, BLTE, and AMRX

How does Bausch Health Cos compare to Crinetics Pharmaceuticals?

Summary

How does Bausch Health Cos compare to Liquidia?

Summary

How does Bausch Health Cos compare to Lantheus?

Summary

How does Bausch Health Cos compare to Belite Bio?

Summary

How does Bausch Health Cos compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Cos (BHC) Competitors

BHC vs. CRNX, LQDA, LNTH, BLTE, and AMRX

How does Bausch Health Cos compare to Crinetics Pharmaceuticals?

Do analysts prefer BHC or CRNX?

Which has more risk & volatility, BHC or CRNX?

Do institutionals and insiders have more ownership in BHC or CRNX?

Which has stronger earnings & valuation, BHC or CRNX?

Is BHC or CRNX more profitable?

Does the media refer more to BHC or CRNX?

Summary

How does Bausch Health Cos compare to Liquidia?

Do analysts recommend BHC or LQDA?

Is BHC or LQDA more profitable?

Does the media favor BHC or LQDA?

Which has better earnings and valuation, BHC or LQDA?

Do institutionals & insiders have more ownership in BHC or LQDA?

Which has more volatility and risk, BHC or LQDA?

Summary

How does Bausch Health Cos compare to Lantheus?

Do insiders and institutionals believe in LNTH or BHC?

Do analysts recommend LNTH or BHC?

Which has better earnings & valuation, LNTH or BHC?

Which has more risk and volatility, LNTH or BHC?

Does the media prefer LNTH or BHC?

Is LNTH or BHC more profitable?

Summary

How does Bausch Health Cos compare to Belite Bio?

Do analysts rate BHC or BLTE?

Which has more volatility and risk, BHC or BLTE?

Does the media refer more to BHC or BLTE?

Is BHC or BLTE more profitable?

Do insiders and institutionals hold more shares of BHC or BLTE?

Which has better valuation and earnings, BHC or BLTE?

Summary

How does Bausch Health Cos compare to Amneal Pharmaceuticals?

Do analysts prefer AMRX or BHC?

Do insiders & institutionals have more ownership in AMRX or BHC?

Does the media prefer AMRX or BHC?

Which has more volatility and risk, AMRX or BHC?

Which has preferable valuation & earnings, AMRX or BHC?

Is AMRX or BHC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools